Dr. Sima C. Jeha
Claim this profileSt. Jude Children's Research Hospital
Studies Acute Lymphoblastic Leukemia
Studies Burkitt Lymphoma
3 reported clinical trials
3 drugs studied
Area of expertise
1Acute Lymphoblastic Leukemia
CD22 positive
2Burkitt Lymphoma
CD22 positive
Philadelphia chromosome positive
Affiliated Hospitals
Clinical Trials Sima C. Jeha is currently running
Inotuzumab Ozogamicin
for Leukemia and Lymphoma
This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back (relapsed) or does not respond to treatment (refractory). Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called ozogamicin. Inotuzumab attaches to CD22 positive cancer cells in a targeted way and delivers ozogamicin to kill them.
Recruiting1 award Phase 210 criteria
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This trial is a limited multi-center, Phase II study to evaluate inotuzumab ozogamicin (Besponsa) in pediatric patients with MRD positive CD22-positive B-lymphoblastic leukemia (B-ALL). Some patients with newly diagnosed ALL maintain low levels of MRD, despite achieving complete remission with less than 5% blasts in the bone marrow. Others experience re-emergence of low level MRD or increasing levels of MRD on therapy or post-transplant. New approaches are needed to achieve undetectable MRD in these high-risk patients. Inotuzumab ozogamicin is an antibody-drug conjugate composed of a humanized IgG subtype 4 monoclonal CD22-targeted antibody linked to calicheamicin, a potent anti-tumor antibiotic. CD22 is expressed in more than 90% of patients with B-cell ALL, making it an attractive target in this patient population. Inotuzumab ozogamicin has demonstrated exceptional activity in adults with relapsed or refractory B-ALL. Primary Objective * Assess the efficacy of inotuzumab ozogamicin in patients with MRD positive CD22+ B-ALL with 0.1 - 4.99% blasts in bone marrow. Secondary Objectives * Study the safety of inotuzumab ozogamicin when used in patients with MRD - positive CD22+ B-ALL with \< 5 % blasts in bone marrow. * Estimate the incidence, severity, and outcome of hepatotoxicity and sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) in patients during inotuzumab ozogamicin and following subsequent treatment, including hematopoietic stem cell transplant (HSCT).
Recruiting1 award Phase 215 criteria
More about Sima C. Jeha
Clinical Trial Related9 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Sima C. Jeha has experience with
- Inotuzumab Ozogamicin
- Bortezomib
- Vorinostat
Breakdown of trials Sima C. Jeha has run
Acute Lymphoblastic Leukemia
Burkitt Lymphoma
B-Cell Lymphoblastic Leukemia-Lymphoma
Childhood Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Sima C. Jeha specialize in?
Sima C. Jeha focuses on Acute Lymphoblastic Leukemia and Burkitt Lymphoma. In particular, much of their work with Acute Lymphoblastic Leukemia has involved CD22 positive patients, or patients who are undergoing treatment.
Is Sima C. Jeha currently recruiting for clinical trials?
Yes, Sima C. Jeha is currently recruiting for 2 clinical trials in Memphis Tennessee. If you're interested in participating, you should apply.
Are there any treatments that Sima C. Jeha has studied deeply?
Yes, Sima C. Jeha has studied treatments such as Inotuzumab Ozogamicin, Bortezomib, Vorinostat.
What is the best way to schedule an appointment with Sima C. Jeha?
Apply for one of the trials that Sima C. Jeha is conducting.
What is the office address of Sima C. Jeha?
The office of Sima C. Jeha is located at: St. Jude Children's Research Hospital, Memphis, Tennessee 38105 United States. This is the address for their practice at the St. Jude Children's Research Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.